NEWARK, Calif.--(BUSINESS WIRE)--Sep. 24, 2018--
Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company
developing neuromodulators for use in treating aesthetic and therapeutic
conditions, today announced that the Company will participate in the
Cantor Fitzgerald 2018 Global Healthcare Conference in New York, NY.
President and Chief Executive Officer, Dan Browne, is scheduled to
present on Tuesday, October 2 at 11:30am ET.
Interested parties can access the live audio webcast for this conference
from the Investor Relations section of the company's website at www.revance.com.
The webcast replay will be available after the conclusion of the live
presentation for approximately 30 days.
About Revance Therapeutics, Inc.
Revance Therapeutics is an emerging Silicon Valley biotechnology leader
developing neuromodulators for the treatment of aesthetic and
therapeutic conditions. Revance uses a unique proprietary, stabilizing
excipient peptide technology to create novel, differentiated therapies.
The company’s lead compound, DaxibotulinumtoxinA for Injection (RT002),
is in clinical development for a broad range of aesthetic and
therapeutic indications, including glabellar lines, cervical dystonia,
plantar fasciitis, upper limb spasticity and chronic migraine. RT002 has
the potential to be the first long-acting neuromodulator. The company is
advancing a robust pipeline of injectable and topical formulations of
daxibotulinumtoxinA. More information on Revance may be found at www.revance.com.
“Revance Therapeutics” and the Revance logo are registered trademarks of
Revance Therapeutics, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180924005655/en/
Source: Revance Therapeutics, Inc.
INVESTORS
Revance Therapeutics, Inc.
Jeanie Herbert, (714)
325-3584
jherbert@revance.com
or
Burns
McClellan, Inc.
Ami Bavishi, (212) 213-0006
abavishi@burnsmc.com
or
MEDIA
General
Media:
TOGORUN
Mariann Caprino, (917) 242-1087
m.caprino@togorun.com
or
Trade
Media:
Nadine Tosk, (504) 453-8344
nadinepr@gmail.com